|
1
|
Cardoso PG, Macedo GC, Azevedo V and
Oliveira SC: Brucella spp noncanonical LPS: structure,
biosynthesis, and interaction with host immune system. Microb Cell
Fact. 5:132006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rambow-Larsen AA, Petersen EM, Gourley CR
and Splitter GA: Brucella regulators: self-control in hostile
environment. Trends Microbiol. 17:371–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pappas G, Papadimitriou P, Akritidis N,
Christou L and Tsianos EV: The new global map of human brucellosis.
Lancet Infect Dis. 6:91–99. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ficht TA, Kahl-McDonagh MM, Arenas-Gamboa
AM and Rice-Ficht AC: Brucellosis: the case for live, attenuated
vaccines. Vaccine. 27:D40–D43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spink WW, Hall JW, Finstad J and Mallet E:
Immunization with viable Brucella organisms. Results of a safety
test in humans. Bull World Health Organ. 26:409–419.
1962.PubMed/NCBI
|
|
6
|
Fugier E, Pappas G and Gorvel JP:
Virulence factors in brucellosis: implications for
aetiopathogenesis and treatment. Expert Rev Mol Med. 9:1–10. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bundle DR, Cherwonogrodzky JW, Gidney MA,
Meikle PJ, Perry MB and Peters T: Definition of Brucella A and M
epitopes by monoclonal typing reagents and synthetic
oligosaccharides. Infect Immun. 57:2829–2836. 1987.PubMed/NCBI
|
|
8
|
Weynants V, Gilson D, Cloeckaert A, Tibor
A, Denoel PA, Godfroid F, Limet JN and Letesson JJ:
Characterization of smooth lipopolysaccharides and O
polysaccharides of Brucella species by competition binding assays
with monoclonal antibodies. Infect Immun. 65:1939–1943.
1997.PubMed/NCBI
|
|
9
|
Ugalde JE, Comerci DJ, Leguizamón MS and
Ugalde RA: Evaluation of Brucella abortus phosphoglucomutase
(pgm) mutant as a new live rough-phenotype vaccine. Infect Immun.
71:6264–6269. 2003.PubMed/NCBI
|
|
10
|
Lapaque N, Moriyon I, Moreno E and Gorvel
JP: Brucella lipopolysaccharide acts as a virulence factor. Curr
Opin Microbiol. 8:60–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fernandez-Prada CM, Zelazowska EB,
Nikolich M, Hadfield TL, Roop RM 2nd, Robertson GL and Hoover DL:
Interactions between Brucella melitensis and human phagocytes:
bacterial surface O-Polysaccharide inhibits phagocytosis, bacterial
killing, and subsequent host cell apoptosis. Infect Immun.
71:2110–2119. 2003. View Article : Google Scholar
|
|
12
|
Jiménez de Bagüés MP, Terraza A, Gross A
and Dornand J: Different responses of macrophages to smooth and
rough Brucella spp: relationship to virulence. Infect Immun.
72:2429–2433. 2004.PubMed/NCBI
|
|
13
|
Moriyón I, Grilló MJ, Monreal D, González
D, Marín C, López-Goñi I, Mainar-Jaime RC, Moreno E and Blasco JM:
Rough vaccines in animals brucellosis: structural and genetic basis
and present status. Vet Res. 35:1–38. 2004.PubMed/NCBI
|
|
14
|
Adone R, Ciuchini F, Marianelli C,
Tarantino M, Pistoia C, Marcon G, Petrucci P, Francia M, Riccardi G
and Pasquali P: Protective properties of rifampin-resistant rough
mutants of Brucella melitensis. Infect Immun. 73:4198–4204. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Haag AF, Myka KK, Arnold MF,
Caro-Hernández P and Ferguson GP: Importance of lipopolysaccharide
and cyclic β-1,2-glucans in Brucella-mammalian infections. Int J
Microbiol. 2010:1245092010.
|
|
16
|
Cloeckaert A, Grayon M, Verger JM,
Letesson JJ and Godfroid F: Conservation of seven genes involved in
the biosynthesis of the lipopolysaccharide O-side chain in Brucella
spp. Res Microbiol. 151:209–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Godfroid F, Cloeckaert A, Taminiau B,
Danese I, Tibor A, de Bolle X, Mertens P and Letesson JJ: Genetic
organization of the lipopolysaccharide O-antigen biosynthesis
region of Brucella melitensis 16M (wbk). Res Microbiol.
151:655–668. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Allen CA, Adams LG and Ficht TA:
Transposon-derived Brucella abortus rough mutants are
attenuated and exhibit reduced intracellular survival. Infect
Immun. 66:1008–1016. 1998.PubMed/NCBI
|
|
19
|
Tsai CM and Frasch CE: A sensitive silver
stain for detecting lipopolysaccharides in polyacrylamide gels.
Anal Biochem. 119:115–119. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ried JL and Collmer A: An nptI-sacB-sacR
cartridge for constructing directed, unmarked mutations in
gram-negative bacteria by marker exchange-eviction mutagenesis.
Gene. 57:239–246. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Orduna A, Almaraz A, Prado A, Gutierrez
MP, Garcia-Pascual A, Dueñas A, Cuervo M, Abad R, Hernández B,
Lorenzo B, Bratos MA and Torres AR: Evaluation of an
immunocapture-agglutination test (Brucellacapt) for serodiagnosis
of human brucellosis. J Clin Microbiol. 38:4000–4005.
2000.PubMed/NCBI
|
|
22
|
Seleem MN, Boyle SM and Sriranganathan N:
Brucellosis: a re-emerging zoonosis. Vet Microbiol. 140:392–398.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Raetz CR and Whitfield C:
Lipopolysaccharide endotoxins. Annu Rev Biochem. 71:635–700. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
González D, Grilló MJ, De Miguel MJ, Ali
T, Arce-Gorvel V, Delrue RM, Conde-Alvarez R, Muñoz P, López-Goñi
I, Iriarte M, Marín CM, Weintraub A, Widmalm G, Zygmunt M, Letesson
JJ, Gorvel JP, Blasco JM and Moriyón I: Brucellosis vaccines:
assessment of Brucella melitensis lipopolysaccharide rough mutants
defective in core and O-polysaccharide synthesis and export. PLoS
One. 3:e27602008.
|
|
25
|
Langford MJ and Myers RC: Difficulties
associated with the development and licensing of vaccines for
protection against bio-warfare and bio-terrorism. Dev Biol (Basel).
110:107–112. 2002.PubMed/NCBI
|
